Active Substance: Interferon beta-1a.
Overview
Welcome to Dwaey, specifically on REBIF 44mcg page.
This medicine contains an important and useful components, as it consists of
Interferon beta-1ais available in the market in concentration
Interferon Beta 1a
Caution when used in patients with depression or psychiatric disorders, epilepsy or other CNS diseases, poorly controlled thyroid dysfunction, pulmonary disease, DM, renal or hepatic impairment, cardiac disorders, myelosuppression, auto-immune diseases, coagulation disorders, or a history of these conditions. Monitor blood counts especially in patients at high risk of myelosuppression. Eye examination should be conducted prior to starting treatment and regularly thereafter. Monitor hepatic and renal function regularly. Treatment should be discontinued in patients with chronic hepatitis who develop liver decompensation. May affect ability to drive or operate machinery. Pregnancy. Lactation: unknown; use caution
Multiple Sclerosis
Hypersensitivity to beta interferons, albumin (for albumin-containing formulations)
>10% Injection site reactions (83% [SC]; 28% [IM],Headache (67%),Flu-like syndrome (61%),Muscle ache (34%),Nausea (33%),URT infection (14%),Pain (24%),Fever (23%),Asthenia (21%),Diarrhea (16%),Dizziness (15%),Infection (11%),Dyspepsia (11%) 1-10% Abdominal pain (9%),Anemia (8%),Chest pain (6%) <1% Aggravation of seizure disorders
3
Interferon beta 1a alters the expression and response to surface antigens and can improve immune cell activities. It has antiviral and immunomodulating properties.
May increase the adverse effects (especially granulocytopenia) of ACE inhibitors. Increased risk of hepatic injury when used with hepatotoxic drugs. May increase serum levels of theophylline derivatives. May increase the anticoagulant effects of warfarin. May decrease the metabolism of zidovudine.
Information not available